Compile Data Set for Download or QSAR
Report error Found 558 with Last Name = 'sakata' and Initial = 'k'
Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621974(US20230312542, Example 1)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621975(US20230312542, Example 6)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621976(US20230312542, Example 14)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621977(US20230312542, Example 15)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621978(US20230312542, Example 16)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621979(US20230312542, Example 17)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621980(US20230312542, Example 18)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621981(US20230312542, Example 19)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621982(US20230312542, Example 20)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621983(US20230312542, Example 21)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621984(US20230312542, Example 22)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621985(US20230312542, Example 23)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621986(US20230312542, Example 24)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621987(US20230312542, Example 25)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621988(US20230312542, Example 29)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621989(US20230312542, Example 30)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621990(US20230312542, Example 31)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621991(US20230312542, Example 35)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621992(US20230312542, Example 40)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621993(US20230312542, Example 44)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621994(US20230312542, Example 48)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621995(US20230312542, Example 49)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621996(US20230312542, Example 51)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621997(US20230312542, Example 53)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621998(US20230312542, Example 54)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621999(US20230312542, Example 61)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622000(US20230312542, Example 62)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622001(US20230312542, Example 63)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622002(US20230312542, Example 64)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622003(US20230312542, Example 65)
Affinity DataKd:  3.00E+4nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622004(US20230312542, Example 66)
Affinity DataKd:  3.00E+4nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622005(US20230312542, Example 69)
Affinity DataKd:  3.00E+4nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622006(US20230312542, Example 74)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622007(US20230312542, Example 75)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622008(US20230312542, Example 76)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622009(US20230312542, Example 78)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622010(US20230312542, Example 79)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622011(US20230312542, Example 80)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622012(US20230312542, Example 81)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622013(US20230312542, Example 84)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622014(US20230312542, Example 89)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622015(US20230312542, Example 90)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622016(US20230312542, Example 91)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622017(US20230312542, Example 93)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622018(US20230312542, Example 96)
Affinity DataKd:  3.00E+4nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622019(US20230312542, Example 97)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622020(US20230312542, Example 102)
Affinity DataKd:  3.00E+4nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622021(US20230312542, Example 107)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622022(US20230312542, Example 108)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622023(US20230312542, Example 111)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 558 total ) | Next | Last >>
Jump to: